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Interleukin-2 (IL-2) is the pivotal cytokine in T cell
differentiation (O'Garra, 1989; Oliver, 1988). Recombinant
interleukin-2 (rIL-2) has been used in cancer treatment
together with in vitro activated lymphocytes (adoptive
immunotherapy) (Rosenberg et al., 1987; von Flidener et al.,
1987; West et al., 1987). IL-2 enhances the cytotoxic activity
of a population of natural killer cells capable of killing
tumour cells through a mechanism independent of the his-
tocompatibility antigens (Malkovsky et al., 1988).
IL-2 acts via interaction with high affinity, cell bound
receptors (IL-2R) (Wang & Smith, 1987). The light chain of
these heterodimeric receptors is identified by monoclonal
antibodies as the Tac antigen (Uchiyama et al., 1981).
A soluble form of IL-2 receptors (sIL-2R), which retains
the ability to bind IL-2, is released by activated lymphoid
cells. Serum levels of sIL-2R can be determined by an
2200
enzyme-linked immunosorbent assay (ELISA) based on the
use of two monoclonal antibodies recognising two different
epitopes of the light (p) chain of IL-2R. Extraordinarily high
levels of sIL-2R are characteristic of hairy cell leukaemia,
whose cells are known to express IL-2R. Smaller increases of
sIL-2R have been reported in several conditions, including
haematological neoplasia (Pizzolo et al., 1987a, b), acquired
immunodeficiencies (Kloster et al., 1987), organ transplanta-
tion (Colvin et al., 1987) and granulomatous disorders
(Lawrence et al., 1987). Scattered data on various solid neo-
plasia indicate an increase of sIL-2R (Rovelli et al., 1988),
while a study aimed to breast cancer did not find any
significant variation of this parameter (Nelson et al., 1987).
The biological relevance of sIL-2R is still unclear. Their
capacity to bind IL-2 suggests that they may modulate the
action of this cytokine by competing with cell bound recep-
tors. In this study we measured sIL-2R in serum from
patients with lung cancer to see if changes relate to the type
or stage of malignancy.
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Figure 1 sIL-2R levels in serum of 41 normal subjects (N) and
43 patients with lung cancer (T). Horizontal lines represent
medians of the values. P < 0.0001.
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Figure 2 sIL-2R levels in serum of 26 patients with lung cancer
divided into stages (1, 11, III and IV) according to TNM
classification (UICC, Geneva, 1978). (*) Squamous carcinoma;
(0) adenocarcinoma; (+) unclassified carcinoma; (0) small cell
carcinoma.
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We studied 43 caucasian patients (33 males and 10 females,
age 63 ± 10 years) affected with small cell lung cancer (nine
patients), and non-small cell lung cancer (34 patients) of
different hystological type (squamous carcinoma, adenocar-
cinoma, unclassified carcinoma). The patients included in this
study did not previously receive any treatment. Co-existing
infections were excluded on the basis of clinical criteria along
with the absence of leukocytosis and positive cultures of
body fluids. Clinical staging was possible in 26 patients and
was performed according to the TNM classification of the
UICC (1978). Levels of sIL-2R were determined with the
commercial Cell Free IL-2R Test Kit (T Cell Science, Cam-
bridge, MA, USA). Forty-one healthy individuals, sex and
age matched with the patients, served as the reference group.
Statistical evaluation was performed by Kruskal-Wallis
analysis of variance, and the significances of differences
between groups were assessed by the non-parametric test of
Mann-Whitney and Wilcoxon.
Median values of sIL-2R were significantly higher
(P <0.0001) in patients (821 U ml-') than controls
(495 U ml-') (Figure 1). No significant differences were
found within different histological types, nor within different
disease stages (Figure 2), between metastatic and non-
metastatic patients (stage 1, 2, 3 versus 4).
This study demonstrates that sIL-2R are elevated in lung
cancer. The lack of correlation with either histological type
or disease stage suggests that this finding is not directly
dependant on the tumour cells, but is more likely to be an
aspect of the immunological response elicited by the neo-
plasia. The reason for the absence of such a correlation is not
unequivocal. Constitutional differences in synthesis and/or
catabolism may influence the serum levels of sIL-2R in
different subjects. Longitudinal studies, now in progress on
patients moving from one stage to another, may at least in
part answer these questions. If we accept the hypothesis that
sIL-2R act as a physiological modulator of IL-2 action it will
be interesting to consider their value in predicting the
effectiveness of rIL-2 in cancer treatment.
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